Is Pfizer Inc. a good investment? Pfizer Inc. (PFE.DE) is currently trading at 22.65 EUR.
In terms of valuation, the stock trades at a P/E ratio of 19.53. This valuation is generally in line with the broader market.
Earnings Schedule: Pfizer Inc. is expected to release its next earnings report on July 29, 2026.
For income investors, Pfizer Inc. pays a dividend yield of 6.78%. With a payout ratio of 131%, the dividend appears to be under pressure.
Yes, it pays an annual dividend of 1.72 EUR (6.78% yield).
Pfizer Inc. is classified as a Stock. You can compare it against 13 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of 1.14.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.38 EUR
|
| March 1, 2027 (estimated) | 0.3815 |
| ▸2026 |
1.51 EUR
|
| Dec. 1, 2026 (estimated) | 0.3815 |
| Sept. 3, 2026 (estimated) | 0.3815 |
| June 12, 2026 | 0.3721 |
| March 6, 2026 | 0.3721 |
| ▸2025 |
1.49 EUR
|
| Dec. 1, 2025 | 0.3721 |
| Sept. 2, 2025 | 0.3721 |
| June 13, 2025 | 0.3721 |
| March 7, 2025 | 0.3721 |
| ▸2024 |
1.45 EUR
|
| Dec. 2, 2024 | 0.3634 |
| Sept. 3, 2024 | 0.3634 |
| June 14, 2024 | 0.3634 |
| March 1, 2024 | 0.3634 |
| ▸2023 |
1.42 EUR
|
| Dec. 4, 2023 | 0.3548 |
| Sept. 5, 2023 | 0.3548 |
| June 9, 2023 | 0.3548 |
| March 3, 2023 | 0.3548 |
| ▸2022 |
1.38 EUR
|
| Dec. 5, 2022 | 0.3461 |
| Sept. 6, 2022 | 0.3461 |
| June 10, 2022 | 0.3461 |
| March 4, 2022 | 0.3461 |
| ▸2021 |
1.35 EUR
|
| Dec. 6, 2021 | 0.3375 |
| Sept. 7, 2021 | 0.3375 |
| June 4, 2021 | 0.3375 |
| March 5, 2021 | 0.3375 |
| ▸2020 |
1.32 EUR
|
| Dec. 1, 2020 | 0.3288 |
| Sept. 1, 2020 | 0.3288 |
| June 5, 2020 | 0.3288 |
| March 6, 2020 | 0.3288 |
| ▸2019 |
1.58 EUR
|
| Dec. 2, 2019 | 0.3115 |
| Sept. 3, 2019 | 0.3115 |
| July 31, 2019 | 0.3325 |
| June 7, 2019 | 0.3115 |
| March 1, 2019 | 0.3115 |
| ▸2018 |
1.49 EUR
|
| Dec. 3, 2018 | 0.2942 |
| Sept. 4, 2018 | 0.2942 |
| June 1, 2018 | 0.2942 |
| March 1, 2018 | 0.2942 |
| Jan. 31, 2018 | 0.3140 |
| ▸2017 |
1.45 EUR
|
| Dec. 1, 2017 | 0.3200 |
| Sept. 1, 2017 | 0.2769 |
| June 1, 2017 | 0.2769 |
| March 1, 2017 | 0.2769 |
| Jan. 31, 2017 | 0.2955 |
| ▸2016 |
1.04 EUR
|
| Dec. 1, 2016 | 0.2596 |
| Sept. 1, 2016 | 0.2596 |
| June 1, 2016 | 0.2596 |
| March 2, 2016 | 0.2596 |
| ▸2015 |
0.97 EUR
|
| Dec. 1, 2015 | 0.2423 |
| Sept. 2, 2015 | 0.2423 |
| June 2, 2015 | 0.2423 |
| March 3, 2015 | 0.2423 |
| ▸2014 |
0.90 EUR
|
| Dec. 2, 2014 | 0.2250 |
| Sept. 3, 2014 | 0.2250 |
| June 3, 2014 | 0.2250 |
| March 4, 2014 | 0.2250 |
| ▸2013 |
0.83 EUR
|
| Dec. 3, 2013 | 0.2077 |
| Sept. 4, 2013 | 0.2077 |
| June 4, 2013 | 0.2077 |
| March 5, 2013 | 0.2077 |
| ▸2012 |
1.17 EUR
|
| Dec. 4, 2012 | 0.1904 |
| Aug. 1, 2012 | 0.1904 |
| July 31, 2012 | 0.2032 |
| June 5, 2012 | 0.1904 |
| Feb. 1, 2012 | 0.1904 |
| Jan. 31, 2012 | 0.2032 |
| ▸2011 |
0.69 EUR
|
| Dec. 6, 2011 | 0.1731 |
| Sept. 6, 2011 | 0.1731 |
| June 7, 2011 | 0.1731 |
| March 1, 2011 | 0.1731 |
| ▸2010 |
0.62 EUR
|
| Dec. 1, 2010 | 0.1558 |
| Sept. 1, 2010 | 0.1558 |
| June 1, 2010 | 0.1558 |
| March 2, 2010 | 0.1558 |
| ▸2009 |
2.05 EUR
|
| Dec. 1, 2009 | 0.1384 |
| Sept. 2, 2009 | 0.1384 |
| June 2, 2009 | 0.1384 |
| April 9, 2009 | 0.3461 |
| April 8, 2009 | 0.3694 |
| March 3, 2009 | 0.2769 |
| Jan. 13, 2009 | 0.3115 |
| Jan. 12, 2009 | 0.3325 |
| ▸2008 |
3.04 EUR
|
| Dec. 2, 2008 | 0.2769 |
| Oct. 10, 2008 | 0.3115 |
| Oct. 9, 2008 | 0.3325 |
| Sept. 3, 2008 | 0.2769 |
| July 11, 2008 | 0.3115 |
| July 10, 2008 | 0.3325 |
| June 3, 2008 | 0.2769 |
| April 11, 2008 | 0.3115 |
| April 10, 2008 | 0.3325 |
| March 4, 2008 | 0.2769 |
| ▸2007 |
0.28 EUR
|
| Dec. 4, 2007 | 0.2812 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Pfizer Inc. | Jun 12, 2026 | Paid | 0.372079 EUR |
| Pfizer Inc. | Mar 06, 2026 | Paid | 0.372079 EUR |
| Pfizer Inc. | Dec 01, 2025 | Paid | 0.372079 EUR |
| Pfizer Inc. | Sep 02, 2025 | Paid | 0.372079 EUR |
Community Discussion